Drug solutions manufacturer Stevanato Group secures €200 million in financial backing
Stevanato Group, a leading Italian company in the pharmaceutical sector, has secured €200 million in financing to support ongoing capital investment projects aimed at expanding production capacity at its facilities in Cisterna di Latina, Italy, and Fishers, Indiana, USA.
The funds, totalling €200 million, will be used to enhance pre-filled syringe production, develop ready-to-use (RTU) cartridge capacity at the Italian plant, boost pre-filled syringe manufacturing in both locations, and complete a new device production area in Fishers, Indiana.
Specifically, €50 million from Cassa Depositi e Prestiti (CDP) will be allocated to expanding pre-filled syringe lines and developing RTU cartridge capacity in Cisterna di Latina. €100 million from BNL BNP Paribas and €50 million from Banco BPM will support scaling up pre-filled syringe manufacturing in both Italy and the U.S., alongside completing the device production area in Fishers, Indiana.
Marco Dal Lago, Chief Financial Officer of Stevanato Group, stated that these agreements are an important element to the Company's financial strategy. Enrico Lemmo, Head of Corporate Banking North-East at Banco BPM, remains committed to standing alongside businesses like Stevanato Group, providing effective financial instruments to support their growth and consolidation plans both in Italy and internationally.
Gianluca Mariani, Head of Industrial Manufacturing, Large Corporate Banking at BNL BNP Paribas, expresses commitment to partnering with companies that invest in innovation, sustainability, and global expansion. Marco Roberto Pessione, Head of Corporate Coverage at CDP, is proud to support Stevanato Group, a symbol of Italian industrial excellence worldwide, in its growth journey.
The financing will help Stevanato Group achieve its long-term organic growth objectives in its key end-markets, as previously stated. The investments are part of the company’s broader capital expenditure program focused on innovation, sustainability, and global expansion.
In the second quarter of 2025, this expansion contributed to the company’s revenue growth (+8% year-over-year to €280 million) and improved margins, reflecting increased volumes and sales particularly in high-value syringes and cartridges. The financing also aligns with Stevanato’s goal to capitalize on rising biologics demand and pharmaceutical advancements.
The agreements will support Stevanato Group’s capacity expansion efforts and the scaling of commercial production to support customers' growing biologics programs. The funds will help Stevanato Group support its customers' biopharmaceutical programs with its unique value proposition of offering integrated solutions across the pharmaceutical value chain.
The financing from CDP, BNL BNP Paribas, and Banco BPM will help Stevanato Group scale pre-filled syringe production at its facilities in North America (Indiana) and Italy, underpinning its long-term growth strategy in the biopharmaceutical sector. The bank officials reiterate their belief in the value of companies that invest in research, quality, and sustainable development, and make a tangible contribution to the growth of the national economy.
[1] Stevanato Group Press Release, [link to press release] [2] Stevanato Group Q2 2025 Earnings Report, [link to earnings report] [3] Stevanato Group Annual Report 2024, [link to annual report] [4] Stevanato Group Sustainability Report 2024, [link to sustainability report]
